News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 668
- Sources here
- 15
- Companies here
- 13
Active search
668 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Earnings call transcript: Assured Guaranty Q2 2026 profit misses estimates
Assured Guaranty reported Q2 2026 adjusted operating income of $1.23 per share on $195 million revenue, missing analyst estimates. Despite the miss, the company highlighted record book value metrics, significantly lower loss expenses, and a strong pipeline for the second half of the year, …
Assured Guaranty Ltd Q2 2026: Revenue $195M, EPS $0.88— 10-Q Summary
Assured Guaranty Ltd (AGO) reported its Q2 2026 financial results, showing total revenues of $195 million and diluted EPS of $0.88, which is a decrease from the prior year. Net income attributable to the company was $39 million. Business highlights included growth in the …
Assured Guaranty Ltd. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AGO) 2026-08-07
This article first appeared on GuruFocus. Adjusted Operating Income: $55 million, or $1.23 per share, in Q2 2026, a 22% increase year-over-year. Net Earned Premiums: Increased due to higher refundings and scheduled net earned premiums, driven by growth in shorter-duration strategies like fund finance. …
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Protagonist Therapeutics (PTGX) is showing significant upside potential due to notable revisions in its earnings estimates, reflecting growing optimism from analysts. The company's earnings outlook continues to improve, with current-quarter EPS expected to increase by 446.8% and full-year EPS by 280.0%. This positive trend …
Assured Guaranty Ltd. Declares Quarterly Dividend of $0.38 per Common Share
Assured Guaranty Ltd. (NYSE:AGO) has declared a quarterly dividend of $0.38 per common share. The dividend is payable on September 3, 2026, to shareholders of record as of August 20, 2026. Assured Guaranty specializes in credit enhancement products and also operates in asset management …
Assured Guaranty Ltd. (NYSE:AGO) Declares Quarterly Dividend of $0.38
Assured Guaranty Ltd. (NYSE:AGO) announced a quarterly dividend of $0.38 per share, payable on September 3rd to shareholders of record on August 20th. This dividend represents a 1.8% annualized yield, and the company has consistently increased its dividend for the past seven years. Despite …
Protagonist Therapeutics (PTGX) Stock Price Surges After Profit Inflection
Protagonist Therapeutics (PTGX) saw its stock price surge after reporting a significant profit inflection in Q2 2026, with revenue reaching US$213.5 million and basic EPS at US$2.47, a major turnaround from previous losses. This shift is largely attributed to the strong performance of ICOTYDE …
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by California State Teachers Retirement System
The California State Teachers Retirement System increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 22.2% in Q1, now holding 58,677 shares valued at $6.2 million. Despite insider sales totaling $11.5 million in the last 90 days, institutional investors own 98.63% of the company, and …
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside
Protagonist Therapeutics, Inc. (PTGX) has seen its average 12-month price target raised to $152.14 by 14 analysts, up from $148.93. This updated target suggests an 11% potential upside from the August 5 closing price. The consensus rating for PTGX remains "Buy," with 13 analysts …
Chicago Atlantic BDC (LIEN) Projected to Release Earnings on Thursday
Chicago Atlantic BDC (LIEN) is anticipated to announce its Q2 2026 earnings before the market opens on Thursday, August 13th. Analysts predict earnings per share of $0.40 and revenue of $16.23 million. The company outperformed expectations in the previous quarter, reporting $0.44 EPS against …
Agora (API) Expected to Announce Earnings on Thursday
Agora (NASDAQ: API) is anticipated to release its Q2 2026 earnings after the market closes on Thursday, August 13th, with analysts forecasting a loss of $0.1986 per share on revenue of $40.4 million. The company recently traded at $4.15, within a 52-week range of …
Assured Guaranty (NYSE:AGO) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS
Assured Guaranty (NYSE:AGO) reported its quarterly earnings, posting an EPS of $1.23, which missed analyst consensus estimates of $1.51 by $0.28. The company's revenue saw a 30.6% year-over-year decline, though it maintained a net margin of 40.45%. Despite the earnings miss, the company declared …
Trivago N.V. ADS (NASDAQ:TRVG) Price Target Raised to $5.50
Susquehanna has increased its price target for Trivago N.V. ADS (NASDAQ:TRVG) from $3.25 to $5.50, while maintaining a "neutral" rating, suggesting a potential upside of 6.18%. Despite this, analyst sentiment remains cautious, with a consensus rating of "Reduce" and an average price target of …
Agora, Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Agora, Inc. (NASDAQ: API) announced it will report its second quarter 2026 financial results on August 13, 2026, after the close of U.S. markets. The company will host a conference call on the same day at 6 p.m. Pacific Time / 9 p.m. Eastern …
Assured Guaranty (NYSE:AGO) Misses Q2 CY2026 Revenue Estimates
Assured Guaranty (NYSE:AGO) Misses Q2 CY2026 Revenue Estimates Financial guaranty insurer Assured Guaranty (NYSE:AGO) missed Wall Street's revenue expectations in Q2 CY2026, with sales falling 30.6% year on year to $195 million. Its non-GAAP profit of $1.23 per share was 23.2% below analysts' consensus …
Assured Guaranty (AGO) Q2 Earnings Lag Estimates
Assured Guaranty (AGO) came out with quarterly earnings of $1.23 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Agomab Therapeutics NV reported its financial results for the first half of 2026, confirming its outlook for the second half of the year. The company successfully completed its Nasdaq IPO, raising $208 million, which is expected to fund operations into the first half of …
Assured Guaranty posts $39M Q2 net income, adjusted operating EPS $1.23; ABV $189.72
Assured Guaranty reported a net income of $39 million for Q2 2026, with an adjusted operating income of $55 million, or $1.23 per diluted share. The company's adjusted book value per share stood at $189.72 as of June 30, 2026. Assured Guaranty returned $62 …
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M
Protagonist Therapeutics, Inc. (PTGX) announced its Q2 revenue of $213.5 million, surpassing the FactSet estimate of $199.8 million. This report highlights a stronger-than-expected financial performance for the quarter.
Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock
Citigroup has raised its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $175 from $130, maintaining a "buy" rating and implying a 19.78% upside. The company recently exceeded quarterly earnings expectations, reporting $2.29 EPS against $2.24 expected, and revenues of $213.47 million. Despite positive analyst …
Assured Guaranty Ltd. Reports Results for Second Quarter 2026
GAAP Highlights: Net income attributable to Assured Guaranty Ltd. was $39 million, or $0.88 per share,(1) for second quarter 2026. Shareholders' equity attributable to Assured Guaranty Ltd. per share was $126.18 as of June 30, 2026. Gross written premiums (GWP) were $81 million for …
Agomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029
Agomab Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of €30.97 million for the first half of 2026 but secured its financial future by raising $208 million in gross proceeds from a Nasdaq IPO. This capital infusion, bringing their total cash and investments …
Chicago Atlantic Real Estate Finance (NASDAQ:REFI) Lowered to "Hold" Rating by Zacks Research
Zacks Research has downgraded Chicago Atlantic Real Estate Finance (NASDAQ:REFI) from a "strong buy" to a "hold" rating, while Weiss Ratings also cut its rating to "sell." The company now holds an overall "Reduce" consensus rating with an average price target of $14.00. REFI …
Agomab reports €252M cash and expects runway into H1 2029
Agomab (Nasdaq: AGMB) reported a net loss of €31.0 million for the first half of 2026, with €252.0 million in cash and short-term investments as of June 30, 2026. This cash position, bolstered by a $208 million IPO, is expected to fund operations into …
Protagonist Therapeutics stock hits all-time high at 143.43 USD
Protagonist Therapeutics (PTGX) stock has reached an all-time high of $143.43, reflecting strong investor confidence and a 155% return over the past year. The biotech firm, with an $8.83 billion market cap, is projected to see significant revenue growth and profitability by 2026, despite …
PROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00
Leerink Partners has increased its target price for Protagonist Therapeutics, Inc. to $150.00, up from the previous $110.00. This adjustment reflects an updated outlook from the financial firm regarding the biotechnology company. The information was reported by Reuters.